"Antibodies, Neutralizing" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.
| Descriptor ID |
D057134
|
| MeSH Number(s) |
D12.776.124.486.485.114.244 D12.776.124.790.651.114.244 D12.776.377.715.548.114.244
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Neutralizing".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Neutralizing".
This graph shows the total number of publications written about "Antibodies, Neutralizing" by people in this website by year, and whether "Antibodies, Neutralizing" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 1 | 0 | 1 |
| 2010 | 3 | 0 | 3 |
| 2011 | 3 | 5 | 8 |
| 2012 | 4 | 3 | 7 |
| 2013 | 4 | 4 | 8 |
| 2014 | 4 | 3 | 7 |
| 2015 | 5 | 6 | 11 |
| 2016 | 4 | 0 | 4 |
| 2017 | 5 | 0 | 5 |
| 2018 | 7 | 2 | 9 |
| 2019 | 2 | 3 | 5 |
| 2020 | 4 | 6 | 10 |
| 2021 | 10 | 8 | 18 |
| 2022 | 1 | 5 | 6 |
| 2023 | 0 | 9 | 9 |
| 2024 | 3 | 6 | 9 |
| 2025 | 4 | 4 | 8 |
| 2026 | 2 | 6 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Neutralizing" by people in Profiles.
-
H2-O deficiency in B cells or dendritic cells drives retrovirus-neutralizing antibody responses. J Virol. 2026 Sep 22; 100(9):e0085326.
-
Strain-specific differences in the response to egg-derived versus recombinant protein influenza vaccines. J Virol. 2026 Jun 23; 100(6):e0031726.
-
Cellular immune responses 12 months after fractional or standard dose BNT162b2 booster vaccination in Mongolian adults. Front Immunol. 2026; 17:1779435.
-
Dual induction of tissue-resident T and B cell immunity for broad influenza protection with a nanofiber-VLP vaccine. J Nanobiotechnology. 2026 Mar 30; 24(1).
-
Immunogenicity and efficacy over 12 months following a fourth dose of a bivalent mRNA or protein-based COVID-19 vaccine: A randomised controlled trial in Australia. J Infect. 2026 Apr; 92(4):106727.
-
Age-related differences in mRNA vaccine immunogenicity and adjuvancy. Immunol Cell Biol. 2026 Apr; 104(4):400-414.
-
The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distances. Vaccine. 2026 Mar 19; 76:128348.
-
DNA origami vaccines program antigen-focused germinal centers. Science. 2026 Feb 05; 391(6785):eadx6291.
-
Elevated SARS-CoV-2 IgG4 in plasma and mucosa following repeated mRNA boosters impact antibody functions to Omicron and sarbecoviruses. EBioMedicine. 2026 Jan; 123:106087.
-
Enhanced In Vivo Tetanus Toxin Neutralizing Potency of an Anti-Toxin Monoclonal Antibody Following Antibody Chimerization. J Biochem Mol Toxicol. 2025 Nov; 39(11):e70595.